Ras
Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.
Ras Isoform Specific Products
All Product Categories
-
Ras Related Products (719)
Related Products (719)
-
Antibodies (36)
-
Ras Isoform Comparison
-
KRAS-IN-43
0 ImagesCat. No.: HY-176250KRAS-IN-43 (Compound 9) is a pan-KRAS inhibitor with IC50 values of 0.15 μM, 0.14 μM, and 0.47 μM against KRASG12V, KRASG12C and wild-type KRAS, respectively. KRAS-IN-43 disrupts the interaction between KRAS and cRAF, and inhibits ERK phosphorylation. KRAS-IN-43 is promising for research of KRAS mutation-related cancers (such as pancreatic cancer, colorectal cancer, and lung cancer).
-
KRAS G13D-IN-2
0 ImagesCat. No.: HY-179452KRAS G13D-IN-2 (compound 8B) is a potent orally active KRAS G13D inhibitor with IC50 values of 1.95 μM (HCT-116G13D) and 2.16 μM (HCT-15G13D). KRAS G13D-IN-2 induces G1-phase arrest and mitochondrial membrane depolarization. KRAS G13D-IN-2 induces senescence through CDK6/TWIST1 inhibition. KRAS G13D-IN-2 inhibits tumor growth in murine models. KRAS G13D-IN-2 can be used for KRASG13D-mutant colorectal cancer research.
-
KRAS inhibitor-37
0 ImagesCat. No.: HY-169311CAS No.: 3058573-95-5KRAS inhibitor-37 (compound 2) is a potent KRAS inhibitor with KDs of 0.004 nM, 0.041 nM, 0.019 nM and 0.144 nM for KRAS wild type, KRAS G12D, KRAS G12C and KRAS G12V by SPR binding assay, respectively. KRAS inhibitor-37 inhibits cell proliferation with IC50s of <2 nM-14 nM for H358, SW620, PANC08.13 cells, respectively. KRAS inhibitor-37 has the potential for cancer research.
-
KRAS-IN-56
0 ImagesCat. No.: HY-182411CAS No.: 2375482-34-9KRAS-IN-56 (Compound 18) is a KRAS inhibitor with an EC50 of 33 μM. KRAS-IN-56 inhibits the interaction between GTP-KRAS and SOS1. KRAS-IN-56 induces a decrease in p-ERK levels. KRAS-IN-56 can be used in research related to lung cancer.
-
JOSD2-IN-1
0 ImagesCat. No.: HY-179058JOSD2-IN-1 (Compound 31) is a covalent JOSD2 inhibitor with an IC50 value of 1.95 μM. JOSD2-IN-1 inhibits JOSD2, thereby down-regulating KRAS expression. JOSD2-IN-1 exhibits significant anti-proliferative activity against HCT116 cells. JOSD2-IN-1 can be used for research on colorectal cancer.
-
KRAS G12D-IN-36
0 ImagesCat. No.: HY-180920KRAS G12D-IN-36 (Compound 53a) is a highly selective and orally active KRAS-G12D inhibitor with an IC50 of 1.63 nM. KRAS G12D-IN-36 effectively inhibits p-ERK with an IC50 of 8.4 nM. KRAS G12D-IN-36 shows potent anti-proliferative activity against AsPC-1 cells. KRAS G12D-IN-36 can be used for research on pancreatic cancer.
-
KRAS inhibitor-35
0 ImagesCat. No.: HY-162976CAS No.: 3030078-96-4KRAS inhibitor-35 (compound 72) is a KRAS inhibitor, with IC50 of 2 nM. KRAS inhibitor-35 can be used in tumor research.
-
KRAS G12C inhibitor 38
0 ImagesCat. No.: HY-143591CAS No.: 2660129-56-4KRAS G12C inhibitor 38 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 38 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129820A1, compound 171).
-
MARY1
0 ImagesCat. No.: HY-174306MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM (human 5-HT2BR). MARY1 induces renal mitochondrial biogenesis (MB) and enhances renal mitochondrial function by increasing mitochondrial respiratory capacity, mitochondrial protein levels, and mitochondrial number in renal proximal tubular cells (RPTCs). MARY1 induces MB through 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK cell signaling pathways in RPTCs. MARY1 can be used to study renal diseases associated with metabolic and mitochondrial dysfunction.
-
KRAS inhibitor-18
0 ImagesCat. No.: HY-146476CAS No.: 2230873-66-0KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC50 of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC50s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers.
-
SCH54292
0 ImagesCat. No.: HY-124161CAS No.: 188480-51-5SCH54292 is a potent Ras-GEF interaction inhibitor with IC50 of 0.7 μM.
-
SOS2 ligand 1
0 ImagesCat. No.: HY-168480CAS No.: 690696-36-7SOS2 ligand 1(compound 2) is a selective ligand of son of sevenless 2 (SOS2) with an KD value of 4.6 µM.
-
Farnesyl thiosalicylic acid amide
0 ImagesCat. No.: HY-112666CAS No.: 1092521-74-8Synonyms: FTS amide; Salirasib amideFarnesyl thiosalicylic acid amide (FTS-A) is an orally active derivative of farnesyl thiosalicylic acid (HY-14754). Farnesyl thiosalicylic acid amide reduces Ras-GTP levels and inhibits cell growth with IC50s of 20 and 10 μM for Panc-1 and U87 cells, respectively. Farnesyl thiosalicylic acid amide can be used for the research of cancer.
-
RTIL 13
0 ImagesCat. No.: HY-115739CAS No.: 1009376-10-6
-
Palmostatin M
0 ImagesCat. No.: HY-152951CAS No.: 1351669-68-5Palmostatin M is a Ras signaling modulator that targets acyl-protein thioesterase 1 (APT1) and 2 (APT2) in cells, with an IC50 of 2.5 nM for APT1. Palmostatin M interferes with the depalmitoylation cycle of Ras and downregulates the overall Ras signaling pathway. Palmostatin M can be used in cancer-related research.
-
KRAS-IN-42
0 ImagesCat. No.: HY-176870CAS No.: 3033641-67-4
-
UC-857993
0 ImagesCat. No.: HY-124514CAS No.: 487001-04-7
